Takeda Announces New Corporate Social Responsibility (CSR) Program Partners in the United States



Takeda announced today that 21 new non-profit organizations in the United States have been awarded grants as part of the company’s $19.5 million commitment to its FY2022 Corporate Social Responsibility program. Takeda is delivering a total of $39.5 million to help improve equity among under-resourced communities in the areas of health, education, the environment, and providing access to healthy foods, in addition to its initial investment of $20 million in FY2021.

Takeda’s U.S. Corporate Social Responsibility grant applications are reviewed on a rolling basis from the start of its fiscal year (April) to the end of the fiscal year (March) . Takeda collaborates with local and regional organizations that share its values and commitment to improving people’s lives and are aligned with its philanthropic focus areas.

Highlights and progress on the company’s US Corporate Social Responsibility program are further detailed in the Takeda Cares for Communities Report, a comprehensive look at the initiatives and partnerships that are making a difference in the lives of communities across the country.

Learn more about Takeda’s Corporate Social Responsibility Program in the United States and our philanthropic strategy here. More information about Takeda’s Global CSR Program can be found here.

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, dedicated to discovering and delivering life-changing treatments while guided by our commitment to patients, our people, and the environment. Takeda’s research and development efforts are focused on four therapeutic areas: oncology, rare genetics and hematology, neuroscience, and gastroenterology (GI), with expertise in immune and inflammatory diseases. We also invest in targeted R&D in Plasma-Derived Therapies and Vaccines. By advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline, we are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives.

Related Stories